Continuing Treatment for Participants Who Have Participated in a Prior Protocol Investigating Elotuzumab
Completed · Phase 2 · NCT02719613
Conditions: Multiple Myeloma
At a glance
- Research payments reported, 2025
- $133,270
- U.S. investigators named
- 7
- Sites paid
- 7
- Planned or actual enrollment
- 67
About the trial
- Sponsor
- Bristol-Myers Squibb (with AbbVie)
- Tested
- Elotuzumab (drug), Dexamethasone (drug), Dexamethasone (drug), Lenalidomide (drug), Bortezomib (drug), Pomalidomide (drug), Nivolumab (drug)
- Dates
- Started 2016-07-15; completion 2026-02-23
- Results posted
- Not yet
The purpose of this study is to continue to provide elotuzumab and/or other study drugs to participants who have participated on a prior protocol investigating elotuzumab who are not able to receive commercial drug supply.
From ClinicalTrials.gov, last updated 2026-04-15. Full record, eligibility and contacts (opens in a new tab)
Industry funding
E.r. Squibb & Sons, L.l.c. reported $133,270 in research payments for this study in 2025 (7 payments).
Products named: Empliciti
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Manuel Modiano, M.D. Hematology & Oncology · Tucson, AZ
- James R. Berenson, M.D. Research Study Specialist · West Hollywood, CA
- Alan Cartmell, M.D. Specialist · Bakersfield, CA
- Suprith Badarinath, MD Hematology & Oncology · Jacksonville, FL
- Sagar Lonial, M.D. Hematology · Atlanta, GA
- Paul G. Richardson, MD Hematology & Oncology · Boston, MA
- Kristi J. Mcintyre, MD Medical Oncology · Dallas, TX
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Dana-Farber Cancer Institute $35,024
- Texas Onco Southwest Fort Worth $26,141
- Cbcc PAin Medicine & Surgery $24,400
- Emory University Hospital, GA $21,391
- James R Berenson MD Incorporated $20,263
- Acrc/arizona Clinical Research Center, Incorporated $5,968
- Cancer Specialists, Llc $83
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.